Pan Cancer T’s approach includes two differentiating elements. First, it exploits unique targets for T-cells that are exclusively expressed by multiple solid cancers. Second, it applies innovative technologies to select naturally occurring and highly specific TCRs that recognize these targets, as well as immune-modulating treatments to overcome tumor micro-environmental challenges in the targeted cancers. The company has ongoing R&D programs to develop safe and effective adoptive T cell therapies amenable to large cohorts of patients with triple negative breast cancer, bladder cancer ovarian, lung adenocarcinoma, or glioma.